Impulse Dynamics Pockets $158M for Heart Failure Therapy

Impulse Dynamics, a company focused on heart failure treatment, has raised over $158 million in financing to boost commercialization, as well as fuel its clinical and technology pipelines.

The investment was anchored by new institutional investors, including Sands Capital and Braidwell. It was also supported by returning investors Redmile, Perceptive, and Alger, and several prominent industry executives.

The company said the proceeds will support its INTEGRA-D and AIM HIGHer clinical trials for its cardiac contractility modulation (CCM) therapy for heart failure. CCM therapy leverages the company’s Optimizer implant, which delivers precisely timed electrical pulses to heart for five hours every day in one-hour treatments. Impulse Dynamics touts it as a new way to improve the heart’s pumping action in patients with heart failure.

“Impulse Dynamics is uniquely positioned to fill a critical gap in HF care: providing symptom relief for patients who have limited treatment options beyond medications,” said Guido Neels, Impulse Dynamics’ chairman. “The organization has successfully built a strong foundation of clinical evidence and is advancing a promising pipeline of next-generation technologies, including the investigational CCM-D HF System.”

The CCM-D HF system will be evaluated in the upcoming multicenter INTEGRA-D trial in the U.S. It aims to assess the investigational system’s potential to improve upon tradition implantable cardioverter-defibrillator (ICD) therapy, which delivers therapy but doesn’t treat heart failure symptoms.

The AIM HIGHer trial is evaluating CCM therapy in U.S. patients with diastolic heart failure, who represent about half of all heart failure patients. There are currently minimal treatment options for these patients, and CCM therapy is already indicated for them in Europe.

The news follows the recent Centers for Medicare and Medicaid Services (CMS) announcement issuing a National Coverage Determination (NCD) for CCM therapy, expanding access to the therapy. CCM therapy for heart failure patients was one of the five therapies chosen for the Transitional Coverage for Emerging Technologies (TCET) pathway in 2025.

“This support recognizes the evidence-based outcomes of CCM therapy, with over 12,000 patients implanted to date, and opens the pathway to greater care for HF patients.” said Jason Spees, CEO of Impulse Dynamics. “As the NCD removes a significant barrier to access by providing coverage and reimbursement for a substantial patient population, this investment will help expand access to CCM therapy to more HF patients in need.  Furthermore, it will accelerate the ongoing development and future commercialization of the CCM-D HF System, a single device designed to deliver CCM therapy for the treatment of HF symptoms along with life-saving, ICD therapy.”